Invest in us
Investing in iQur is investing in the future. No virus has ever been eradicated through drug therapy; vaccines alone work. 250,000 to 500,000 people die each year from flu epidemics; 584,000 die from malaria; 500,000 die from hepatitis C related liver diseases. Investing in iQur is investing in lives in your city, your country, the world.
An inestment in the Company is intended for EIS reliefs.
Investments of this nature carry risks to your capital as well as potential rewards. Please read our risk warning and the important noticebefore deciding to invest.
For more on investment opportunities at iQur, contact CEO, William Rosenberg
Investment in biotech
Biotechnology companies were among the most popular and best performing investment opportunities in 2014. One of the UK’s best proven stock-pickers, Neil Woodford, says of investing in British biotechs:
“We have some world-class science in the UK, and it probably won’t take much in the way of positive progress to change the market’s perception of this sector. I believe we are on the cusp of some extraordinary breakthroughs in the UK’s life sciences industry and I am very excited about the long-term value opportunity.” (Telegraph, 2014)
The technological and scientific advancements in a start-up drug company make them fruitful opportunities for portfolio investors.
Investment in iQur
iQur, with vaccines in development for phase I testing next year, poses an exciting opportunity for investors, with a clear strategy for further development, early rounds of successful research, and relatively modest investment options.
iQur is a private company, opening a new round of investment in Q4 2015.
As well as private investment, iQur has been successful in obtaining international grants. iQur leads a consortium that won £3.8 million funding from the EU Framework 7 Program to develop a universal influenza vaccine. In 2013 we successfully applied to the TSB-MRC Biocatalyst Fund to apply the Tandem Core platform to malaria in collaboration with Professor Adrian Hill at the Jenner Institute, University of Oxford. Funding from the TSB also supports a joint program with DTRA developing vaccines for Burkholderia.
The company is governed by a Board who have adopted corporate governance guidelines, to ensure best practice in iQur’s growth, to promote the interests of stockholders, and to establish a set of common principles by which the company will be managed by investors and directors.